Figure 4. . A strategy for personalized epi-immunotherapy.

Using a liquid biopsy approach (e.g., from a blood sample) relevant information about cancer-specific mutations and epigenetic alterations (H3K27me3) levels can be obtained. The first information will enable clinicians to select the optimal immunotherapy, while the latter is useful to identify cancers with higher EZH2 activity and therefore more sensitive to EZH2 inhibitors. The same approach can be employed for dynamic monitoring of cancer progression during the therapy.